| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 42 | 2025 | 96 | 6.210 |
Why?
|
| Severe Combined Immunodeficiency | 11 | 2025 | 53 | 2.480 |
Why?
|
| Cystic Fibrosis | 15 | 2010 | 110 | 2.290 |
Why?
|
| Infant, Newborn | 52 | 2025 | 1286 | 1.790 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2025 | 281 | 1.100 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2015 | 37 | 0.690 |
Why?
|
| Genetic Testing | 6 | 2010 | 126 | 0.670 |
Why?
|
| Polymerase Chain Reaction | 11 | 2012 | 495 | 0.640 |
Why?
|
| Algorithms | 8 | 2010 | 978 | 0.610 |
Why?
|
| Immunologic Deficiency Syndromes | 5 | 2019 | 67 | 0.610 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2018 | 13 | 0.610 |
Why?
|
| Pilots | 1 | 2018 | 9 | 0.610 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 328 | 0.610 |
Why?
|
| Trypsinogen | 5 | 2010 | 6 | 0.590 |
Why?
|
| DNA Mutational Analysis | 6 | 2010 | 188 | 0.590 |
Why?
|
| Infant | 16 | 2025 | 1493 | 0.530 |
Why?
|
| Massachusetts | 11 | 2021 | 2022 | 0.460 |
Why?
|
| T-Lymphocytes | 7 | 2018 | 986 | 0.450 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 5 | 2010 | 74 | 0.440 |
Why?
|
| Humans | 61 | 2025 | 59437 | 0.410 |
Why?
|
| Program Development | 3 | 2010 | 203 | 0.380 |
Why?
|
| Health Plan Implementation | 2 | 2010 | 40 | 0.370 |
Why?
|
| Genetic Counseling | 3 | 2005 | 15 | 0.360 |
Why?
|
| Program Evaluation | 5 | 2016 | 470 | 0.360 |
Why?
|
| Hematologic Tests | 1 | 2010 | 15 | 0.350 |
Why?
|
| Immunoassay | 3 | 2010 | 68 | 0.350 |
Why?
|
| DNA, Viral | 4 | 2008 | 223 | 0.340 |
Why?
|
| Mutation | 10 | 2018 | 2458 | 0.340 |
Why?
|
| HIV Infections | 9 | 2008 | 913 | 0.330 |
Why?
|
| Pilot Projects | 6 | 2014 | 915 | 0.320 |
Why?
|
| Parents | 3 | 2014 | 367 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 250 | 0.300 |
Why?
|
| Sweat | 4 | 2010 | 4 | 0.280 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 443 | 0.260 |
Why?
|
| Advisory Committees | 3 | 2016 | 108 | 0.250 |
Why?
|
| Diffusion of Innovation | 1 | 2006 | 56 | 0.250 |
Why?
|
| Homeodomain Proteins | 2 | 2018 | 254 | 0.240 |
Why?
|
| Professional Competence | 1 | 2006 | 91 | 0.240 |
Why?
|
| HIV Seropositivity | 3 | 1997 | 82 | 0.240 |
Why?
|
| DNA | 3 | 2010 | 805 | 0.240 |
Why?
|
| Blood Specimen Collection | 5 | 2010 | 19 | 0.240 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 66 | 0.230 |
Why?
|
| Needs Assessment | 1 | 2005 | 187 | 0.230 |
Why?
|
| HIV | 2 | 1996 | 68 | 0.220 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2025 | 89 | 0.220 |
Why?
|
| HIV-1 | 7 | 2008 | 692 | 0.220 |
Why?
|
| Chlorides | 4 | 2010 | 32 | 0.220 |
Why?
|
| Movement Disorders | 1 | 2023 | 22 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 48 | 0.210 |
Why?
|
| Child Health Services | 1 | 2004 | 61 | 0.210 |
Why?
|
| Language Development Disorders | 1 | 2023 | 26 | 0.210 |
Why?
|
| Iduronate Sulfatase | 1 | 2022 | 2 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2010 | 1028 | 0.210 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 292 | 0.200 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2022 | 10 | 0.200 |
Why?
|
| New York | 3 | 2018 | 134 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2022 | 110 | 0.190 |
Why?
|
| False Positive Reactions | 4 | 2010 | 76 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2025 | 6078 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2015 | 651 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2005 | 454 | 0.180 |
Why?
|
| Communication | 1 | 2005 | 547 | 0.180 |
Why?
|
| Sensitivity and Specificity | 7 | 2008 | 1097 | 0.180 |
Why?
|
| Lymphopenia | 3 | 2017 | 35 | 0.180 |
Why?
|
| Genes, T-Cell Receptor | 2 | 2010 | 7 | 0.170 |
Why?
|
| Mannosidase Deficiency Diseases | 1 | 2019 | 1 | 0.170 |
Why?
|
| alpha-Mannosidase | 1 | 2019 | 5 | 0.170 |
Why?
|
| Child | 8 | 2023 | 4194 | 0.170 |
Why?
|
| United States | 14 | 2022 | 7430 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2021 | 177 | 0.160 |
Why?
|
| Decision Making | 3 | 2016 | 395 | 0.150 |
Why?
|
| Chickenpox | 1 | 2018 | 3 | 0.150 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 9 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2018 | 15 | 0.150 |
Why?
|
| Feasibility Studies | 3 | 2010 | 526 | 0.140 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2016 | 7 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 333 | 0.140 |
Why?
|
| New England | 2 | 2010 | 267 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2008 | 394 | 0.140 |
Why?
|
| HIV Antibodies | 3 | 1996 | 133 | 0.130 |
Why?
|
| Phenylketonurias | 1 | 2016 | 1 | 0.130 |
Why?
|
| Adrenoleukodystrophy | 1 | 2016 | 8 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 108 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2008 | 71 | 0.130 |
Why?
|
| Incidence | 4 | 2025 | 1239 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 706 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 61 | 0.120 |
Why?
|
| Aftercare | 2 | 2005 | 71 | 0.120 |
Why?
|
| Models, Organizational | 2 | 2005 | 92 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2015 | 59 | 0.120 |
Why?
|
| Genotype | 4 | 2008 | 619 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 139 | 0.120 |
Why?
|
| AIDS Serodiagnosis | 2 | 1997 | 19 | 0.120 |
Why?
|
| Mass Screening | 3 | 2016 | 648 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2010 | 2339 | 0.110 |
Why?
|
| Third-Party Consent | 1 | 2014 | 9 | 0.110 |
Why?
|
| Disease Management | 1 | 2015 | 220 | 0.110 |
Why?
|
| Intestinal Atresia | 1 | 2013 | 2 | 0.110 |
Why?
|
| Female | 15 | 2025 | 30757 | 0.110 |
Why?
|
| Calibration | 2 | 2010 | 67 | 0.110 |
Why?
|
| Lipids | 1 | 2015 | 301 | 0.100 |
Why?
|
| False Negative Reactions | 3 | 2005 | 40 | 0.100 |
Why?
|
| Leukopenia | 1 | 2012 | 16 | 0.100 |
Why?
|
| DNA, Circular | 1 | 2012 | 7 | 0.100 |
Why?
|
| Child, Preschool | 6 | 2016 | 1794 | 0.100 |
Why?
|
| Intestines | 1 | 2013 | 158 | 0.100 |
Why?
|
| Male | 11 | 2025 | 27775 | 0.090 |
Why?
|
| alpha-Thalassemia | 1 | 2010 | 1 | 0.090 |
Why?
|
| Public Health Practice | 1 | 2010 | 15 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 256 | 0.090 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2010 | 4 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 122 | 0.090 |
Why?
|
| Biomarkers | 3 | 2012 | 1306 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2010 | 32 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2010 | 60 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 725 | 0.090 |
Why?
|
| Quality Control | 1 | 2010 | 71 | 0.090 |
Why?
|
| Expert Testimony | 1 | 2010 | 17 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2010 | 38 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 17 | 0.080 |
Why?
|
| Oropharynx | 1 | 2009 | 12 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 487 | 0.080 |
Why?
|
| Decision Trees | 2 | 2005 | 51 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2025 | 178 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 1560 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2000 | 60 | 0.080 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2008 | 10 | 0.080 |
Why?
|
| Decision Making, Organizational | 2 | 2005 | 25 | 0.070 |
Why?
|
| Developing Countries | 1 | 2008 | 86 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 789 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 730 | 0.070 |
Why?
|
| Genetic Carrier Screening | 2 | 2004 | 14 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 3621 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2010 | 430 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 2006 | 51 | 0.060 |
Why?
|
| Referral and Consultation | 3 | 2005 | 406 | 0.060 |
Why?
|
| Aging | 1 | 1992 | 710 | 0.060 |
Why?
|
| Reference Standards | 1 | 2006 | 71 | 0.060 |
Why?
|
| Iontophoresis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Parental Consent | 1 | 2005 | 6 | 0.060 |
Why?
|
| Physician Executives | 1 | 2005 | 28 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2005 | 94 | 0.060 |
Why?
|
| Risk Factors | 4 | 2025 | 4990 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2006 | 170 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 413 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2005 | 136 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2025 | 90 | 0.060 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 1 | 2023 | 1 | 0.050 |
Why?
|
| Creatine | 1 | 2023 | 24 | 0.050 |
Why?
|
| Virology | 1 | 2003 | 13 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2005 | 279 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 27 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2003 | 259 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 98 | 0.050 |
Why?
|
| Iduronic Acid | 1 | 2022 | 1 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 221 | 0.050 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2022 | 9 | 0.050 |
Why?
|
| Glycosaminoglycans | 1 | 2022 | 18 | 0.050 |
Why?
|
| Public Health | 2 | 2016 | 176 | 0.050 |
Why?
|
| Social Support | 1 | 2005 | 355 | 0.050 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2002 | 20 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2001 | 8 | 0.050 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2001 | 14 | 0.050 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2001 | 11 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 552 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 550 | 0.050 |
Why?
|
| Zidovudine | 1 | 2000 | 12 | 0.040 |
Why?
|
| Informed Consent | 1 | 2002 | 138 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2001 | 191 | 0.040 |
Why?
|
| Health Policy | 1 | 2002 | 177 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 129 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 153 | 0.040 |
Why?
|
| Cellulose | 1 | 1999 | 42 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2004 | 2376 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 1997 | 7 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2018 | 172 | 0.030 |
Why?
|
| Risk | 2 | 2010 | 364 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 114 | 0.030 |
Why?
|
| Globins | 1 | 1996 | 25 | 0.030 |
Why?
|
| Point Mutation | 2 | 2008 | 160 | 0.030 |
Why?
|
| Reference Values | 2 | 2009 | 326 | 0.030 |
Why?
|
| Blood Stains | 1 | 1996 | 1 | 0.030 |
Why?
|
| Blood Preservation | 1 | 1996 | 4 | 0.030 |
Why?
|
| DNA Breaks | 1 | 2016 | 7 | 0.030 |
Why?
|
| Genes, RAG-1 | 1 | 2016 | 8 | 0.030 |
Why?
|
| V(D)J Recombination | 1 | 2016 | 5 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 263 | 0.030 |
Why?
|
| National Health Programs | 1 | 2016 | 13 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1996 | 94 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 119 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 49 | 0.030 |
Why?
|
| Thailand | 2 | 2008 | 94 | 0.030 |
Why?
|
| Specialization | 1 | 2015 | 78 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 446 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 116 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 183 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 64 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 218 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 912 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 30 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 73 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 554 | 0.030 |
Why?
|
| Consanguinity | 1 | 2012 | 6 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2012 | 3 | 0.030 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2012 | 9 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 70 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 98 | 0.030 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 15 | 0.030 |
Why?
|
| Blood | 1 | 1992 | 29 | 0.020 |
Why?
|
| Government Programs | 1 | 2012 | 20 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2013 | 229 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 65 | 0.020 |
Why?
|
| Professional Role | 1 | 2012 | 39 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 63 | 0.020 |
Why?
|
| Prospective Studies | 2 | 1996 | 3069 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 295 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2012 | 45 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 241 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2095 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1992 | 61 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 94 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1992 | 191 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 58 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 65 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2010 | 56 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2002 | 295 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1597 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 97 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2010 | 38 | 0.020 |
Why?
|
| RNA Viruses | 1 | 1989 | 8 | 0.020 |
Why?
|
| Leishmania | 1 | 1989 | 12 | 0.020 |
Why?
|
| Gram-Negative Aerobic Rods and Cocci | 1 | 2009 | 1 | 0.020 |
Why?
|
| Gram-Positive Cocci | 1 | 2009 | 2 | 0.020 |
Why?
|
| Infant Care | 1 | 2008 | 18 | 0.020 |
Why?
|
| Health Personnel | 1 | 2012 | 342 | 0.020 |
Why?
|
| Carnitine | 1 | 2008 | 18 | 0.020 |
Why?
|
| Infant Formula | 1 | 2008 | 11 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1469 | 0.020 |
Why?
|
| Adult | 3 | 2018 | 15695 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 808 | 0.020 |
Why?
|
| Histidine | 1 | 2006 | 34 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 170 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1054 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2008 | 144 | 0.020 |
Why?
|
| Arginine | 1 | 2006 | 110 | 0.020 |
Why?
|
| Pilocarpine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2005 | 7 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2006 | 100 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2006 | 172 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2005 | 91 | 0.010 |
Why?
|
| Linear Models | 1 | 2005 | 403 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 39 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 1926 | 0.010 |
Why?
|
| Infection Control | 1 | 2004 | 95 | 0.010 |
Why?
|
| Health Education | 1 | 2004 | 183 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 465 | 0.010 |
Why?
|
| RNA Stability | 1 | 2003 | 97 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 220 | 0.010 |
Why?
|
| Pregnancy | 2 | 2000 | 2215 | 0.010 |
Why?
|
| Sweating | 1 | 2001 | 26 | 0.010 |
Why?
|
| Electrolytes | 1 | 2001 | 25 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1505 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 162 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 313 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2000 | 38 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 284 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 10300 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 181 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 715 | 0.010 |
Why?
|
| Animals | 2 | 2013 | 19664 | 0.010 |
Why?
|
| Spain | 1 | 1997 | 32 | 0.010 |
Why?
|
| HIV-2 | 1 | 1997 | 23 | 0.010 |
Why?
|
| Puerto Rico | 1 | 1996 | 134 | 0.010 |
Why?
|
| Prevalence | 1 | 1997 | 1254 | 0.010 |
Why?
|
| HIV Antigens | 1 | 1990 | 18 | 0.010 |
Why?
|
| Virus Cultivation | 1 | 1990 | 18 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 138 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 99 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 446 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1989 | 248 | 0.000 |
Why?
|
| Species Specificity | 1 | 1989 | 329 | 0.000 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1989 | 57 | 0.000 |
Why?
|